Regulatory enablement Haffner Associates specializes in regulatory strategy and feasibility assessments for orphan and pediatric programs, offering opportunities to position as a go-to partner for biotech and pharma clients seeking regulatory design, filings, and post-submission support.

Orphan program focus The firm targets rare and devastating diseases with services around orphan drug designations, pediatric vouchers, and breakthrough therapy designations, suggesting a strong sales angle to attract sponsors seeking expedited or incentive-backed approvals.

FDA EMA prep With capabilities to develop meeting materials and facilitate regulatory agency interactions, there is potential to upsell end-to-end regulatory prep packages and advisory services for multinational programs.

Patient engagement Engagement with patient advocacy groups and clinicians opens channels for partnerships and co-development opportunities, enabling partnerships that could drive early access programs and patient-centric study designs.

SMB biotech alignment Revenue positioning indicates a boutique consultancy serving small to mid-sized biotech firms; there is growth potential in scalable advisory bundles and retainer-based engagements for startups needing regulatory pathways and feasibility validation.